Literature DB >> 8157273

In vitro human lymphocyte proliferative responses to a glycoprotein of the yeast Saccharomyces cerevisiae.

C J Darroch1, S E Christmas, R M Barnes.   

Abstract

Following reports of enhanced humoral immunity to Saccharomyces cerevisiae in patients with Crohn's disease, and identification of an immunodominant, high molecular weight glycoprotein (gp200), we have investigated the cellular immune response to this yeast in normal individuals. Following exposure to a crude saline extract (Sacc), peripheral blood mononuclear cells (PBMC) from these subjects demonstrated dose-dependent increases in tritiated thymidine incorporation, the time-course of which resembled that of the response to the known recall antigens PPD and TT. This was accompanied by increased cytotoxicity of the cultured cells for natural killer (NK)-sensitive and NK-resistant target cell lines. Furthermore, using a purified, high molecular weight, glycoprotein fraction of Sacc in culture, a dose-dependent lymphoproliferative response was again observed. Stimulation indices (SI) for thymidine incorporation by umbilical cord blood lymphocytes exposed to Sacc were low compared with those of normal adults. These results provide evidence for possible antigen-specific, cellular, immune sensitization of normal individuals to a ubiquitous dietary component.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157273      PMCID: PMC1422302     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

1.  Cord blood lymphocyte responses to food antigens for the prediction of allergic disorders.

Authors:  N Kondo; Y Kobayashi; S Shinoda; K Kasahara; T Kameyama; S Iwasa; T Orii
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

2.  Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.

Authors:  H McKenzie; J Main; C R Pennington; D Parratt
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

Review 3.  The role of activated T lymphocytes in gastrointestinal disease.

Authors:  T T MacDonald
Journal:  Clin Exp Allergy       Date:  1990-05       Impact factor: 5.018

4.  Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?

Authors:  R M Barnes; S Allan; C H Taylor-Robinson; R Finn; P M Johnson
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

5.  Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions.

Authors:  L Scaringi; P Marconi; M Boccanera; L Tissi; F Bistoni; A Cassone
Journal:  J Gen Microbiol       Date:  1988-05

6.  Lymphoproliferative and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans.

Authors:  A Torosantucci; C Palma; M Boccanera; C M Ausiello; G C Spagnoli; A Cassone
Journal:  J Gen Microbiol       Date:  1990-11

7.  Proliferation of human peripheral blood mononuclear cells induced by Candida albicans and its cell wall fractions.

Authors:  C M Ausiello; G C Spagnoli; M Boccanera; I Casalinuovo; F Malavasi; C U Casciani; A Cassone
Journal:  J Med Microbiol       Date:  1986-11       Impact factor: 2.472

8.  Cytotoxic effectors in human peripheral blood mononuclear cells induced by a mannoprotein complex of Candida albicans: a comparison with interleukin 2-activated killer cells.

Authors:  C M Ausiello; C Palma; G C Spagnoli; A Piazza; C U Casciani; A Cassone
Journal:  Cell Immunol       Date:  1989-07       Impact factor: 4.868

9.  Human lymphocyte-activating properties of a purified polysaccharide from Candida albicans: B and T cell cooperation in the mitogenic response.

Authors:  E Piccolella; G Lombardi; R Morelli
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

10.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29
View more
  7 in total

1.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 2.  Recent advances in the diagnosis and classification of inflammatory bowel disease.

Authors:  Eric Vasiliauskas
Journal:  Curr Gastroenterol Rep       Date:  2003-12

3.  Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.

Authors:  S Peifang; G L Pira; D Fenoglio; S Harris; M G Costa; V Venturino; V Dessì; G Layton; J Laman; J G Huisman
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

4.  Circulating antibodies to Saccharomyces cerevisiae (bakers'/brewers' yeast) in gastrointestinal disease.

Authors:  C J Darroch; R M Barnes; J Dawson
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

5.  Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease.

Authors:  N W Savage; K Barnard; P J Shirlaw; D Rahman; M Mistry; M P Escudier; J D Sanderson; S J Challacombe
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

6.  Characterization of oligosaccharides from an antigenic mannan of Saccharomyces cerevisiae.

Authors:  M Young; M J Davies; D Bailey; M J Gradwell; B Smestad-Paulsen; J K Wold; R M Barnes; E F Hounsell
Journal:  Glycoconj J       Date:  1998-08       Impact factor: 2.916

7.  IgG and IgE immune response against the surface glycoprotein gp200 of Saccharomyces cerevisiae in patients with atopic dermatitis.

Authors:  P Nenoff; B Müller; U Sander; G Kunze; M Bröker; U F Haustein
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.